Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports
BackgroundTrastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2), has demonstrated substantial clinical activity in metastatic HER2-positive breast cancer. Although durable responses are increasingly reported, the potential for long-lasti...
Gardado en:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2025-10-01
|
| Series: | Frontiers in Oncology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1647018/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|